Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1B2 | O75343 | 20/20 | 0.69 |
| ▸ | GUCY1A2 | P33402 | 20/20 | 0.69 |
| ▸ | GUCY1A1 | Q02108 | 20/20 | 0.69 |
| ▸ | GUCY1B1 | Q02153 | 20/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17484142 | 0.91 | GUCY1B2 (0.68) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL18212209 | 0.89 | GUCY1B2 (0.69) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL17481647 | 0.87 | GUCY1B2 (0.71) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1CYP2C9 | |
| SCHEMBL16081984 | 0.86 | GUCY1B2 (0.69) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL16082269 | 0.85 | GUCY1B2 (0.75) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL16907008 | 0.85 | GUCY1B2 (0.68) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL16082276 | 0.85 | GUCY1B2 (0.70) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL16082075 | 0.84 | GUCY1B2 (0.79) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL16082063 | 0.83 | GUCY1B2 (0.71) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 | |
| SCHEMBL16081816 | 0.82 | GUCY1B2 (1.00) | GUCY1B2GUCY1A2GUCY1A1GUCY1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481689-B2 | sGC stimulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20160031903-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031903-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | GUCY1B2 10/4885GUCY1A2 5/4885GUCY1A1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.